Fluvastatin Inhibits Hypoxic Proliferation and p38 MAPK Activity in Pulmonary Artery Fibroblasts
Authors:
- 1 October 2007
- journal article
- Published by Oxford University Press (OUP) in American Journal of Respiratory Cell and Molecular Biology
- Vol. 37 (4) , 447-456
Abstract
The earliest structural change in hypoxia-induced pulmonary hypertension is increased proliferation of adventitial fibroblasts. This fibroproliferative response occurs in acute and chronic hypoxic models, is dependent on p38 mitogen-activated protein (MAP) kinase activation, is selective for the pulmonary circulation, and would seem an important therapeutic target. Simvastatin attenuates pulmonary vascular remodeling in animal models, but additional information regarding mechanisms of action, differential antiproliferative effects and dose responses of available statins is required for appropriate clinical trial design. Our objectives were to determine the effects of statins on acute hypoxia-induced proliferation and p38 MAP kinase activation in pulmonary and systemic artery fibroblasts, to assess the effects of cholesterol intermediates, prenyltransferase and related inhibitors, and to determine the statin's mechanism of action. Atorvastatin, fluvastatin, and simvastatin inhibited adventitial fibroblast proliferation. At low doses (1 μM), this effect was selective for hypoxic (versus serum-induced) proliferation and was also selective for pulmonary (versus systemic) fibroblasts. Complete inhibition of hypoxia-induced p38 MAP kinase activity was achieved at this 1-μM dose. The lipophilic statins exhibited similar potency. The statin effect was reversed by geranylgeranyl pyrophosphate and mimicked by geranylgeranyl transferase and Rac1 inhibitors. Hypoxia-induced p38 MAP kinase activation and proliferation in pulmonary adventitial fibroblasts is dependent on a geranylgeranylated signaling protein, probably Rac1. One micromolar of fluvastatin exhibits a circulation- and stimulus-selective antiproliferative effect on pulmonary artery fibroblasts. The pharmacokinetics of fluvastatin would suggest that its antiproliferative effects may be useful in pulmonary hypertension associated with hypoxia.Keywords
This publication has 50 references indexed in Scilit:
- Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodelingAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2007
- Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertensionAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2006
- Mobility and invasiveness of metastatic esophageal cancer are potentiated by shear stress in a ROCK- and Ras-dependent mannerAmerican Journal of Physiology-Cell Physiology, 2006
- Potential therapeutic role for statins in respiratory diseaseThorax, 2006
- Regulation of NADPH OxidasesCirculation Research, 2006
- Involvement of RhoA/Rho kinase signaling in pulmonary hypertension of the fawn-hooded ratJournal of Applied Physiology, 2006
- Vascular Remodeling Versus Vasoconstriction in Chronic Hypoxic Pulmonary HypertensionCirculation Research, 2005
- Clinical classification of pulmonary hypertensionJACC, 2004
- Mevastatin Can Cause G 1 Arrest and Induce Apoptosis in Pulmonary Artery Smooth Muscle Cells Through a p27 Kip1 -Independent PathwayCirculation Research, 2003
- The 70 kDa S6 Kinase Complexes with and Is Activated by the Rho Family G Proteins Cdc42 and Rac1Cell, 1996